Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 9, 2008, Pages 1241-1247

  Chung, Eun Jee ^a,b   Hong, Young Taek ^b   Lee, Sung Chul ^b   Kwon, Oh Woong ^b   Koh, Hyoung Jun ^b  

^a National Health Insurance Corporation   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Branch retinal vein occlusion; Intravitreal bevacizumab injection; Macular edema; Macular ischemia

Indexed keywords

BEVACIZUMAB; PROXYMETACAINE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; PRIORITY JOURNAL; PROGNOSIS; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROGNOSIS; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 48449106803     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0866-8     Document Type: Article

References (23)

1. Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114:1243-1247
2. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271-282
3. Greer DV, Constable IJ, Cooper RL (1980) Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 8:207-209
4. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611
5. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP (2003) VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 44:2155-2162
6. Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K, Hori S (2005) Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 243:3-8
7. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141-149
8. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 26:279-284
9. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275-278
10. Mulcahy MF, Benson AB 3rd (2005) Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 5:997-1005
11. Mason JO 3rd, Albert MA Jr, Mays A, Vail R (2006) Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26:839-841
12. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999-1005
13. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743-750
14. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601-606
15. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419-425
16. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336-339
17. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I (1982) New visual acuity charts for clinical research. Am J Ophthalmol 94:91-96
18. Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger SG (2008) Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92:351-355
19. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular edema secondary to retinal vein occlusion - a prospective study. Br J Ophthalmol 92:518-522
20. Shilling JS, Jones CA (1984) Retinal branch vein occlusion: A study of argon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol 68:196-198
21. Chen SD, Sundaram V, Lochhead J, Patel CK (2006) Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 141:876-883
22. Gutman FA, Zegarra H (1974) The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 78:OP178-OP192
23. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley KS (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26:871-876